MXPA06002025A - Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero. - Google Patents

Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero.

Info

Publication number
MXPA06002025A
MXPA06002025A MXPA06002025A MXPA06002025A MXPA06002025A MX PA06002025 A MXPA06002025 A MX PA06002025A MX PA06002025 A MXPA06002025 A MX PA06002025A MX PA06002025 A MXPA06002025 A MX PA06002025A MX PA06002025 A MXPA06002025 A MX PA06002025A
Authority
MX
Mexico
Prior art keywords
addiction
treatment
alcohol
mammal
prevention
Prior art date
Application number
MXPA06002025A
Other languages
English (en)
Inventor
Steven Bradley Sands
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06002025A publication Critical patent/MXPA06002025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones farmaceuticas para el tratamiento de la dependencia o adiccion a alcohol o cocaina, dependencia o adiccion a alcohol, reduccion de los sintomas de abstinencia de alcohol o para la ayuda en el cese o reduccion del uso de tabaco o abuso de sustancias u otras dependencias conductuales; las composiciones farmaceuticas estan comprendidas por una combinacion terapeutica eficaz de un agonista parcial del receptor nicotinico y un ligando alfa2delta y un vehiculo farmaceuticamente aceptable; se describe tambien el procedimiento de uso de estos compuestos.
MXPA06002025A 2003-08-22 2004-08-09 Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero. MXPA06002025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49735003P 2003-08-22 2003-08-22
PCT/IB2004/002603 WO2005018621A1 (en) 2003-08-22 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Publications (1)

Publication Number Publication Date
MXPA06002025A true MXPA06002025A (es) 2006-05-17

Family

ID=34216113

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06002025A MXPA06002025A (es) 2003-08-22 2004-08-09 Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero.

Country Status (7)

Country Link
US (1) US20050043407A1 (es)
EP (1) EP1658058A1 (es)
JP (1) JP2007503425A (es)
BR (1) BRPI0413607A (es)
CA (1) CA2535811A1 (es)
MX (1) MXPA06002025A (es)
WO (1) WO2005018621A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
RU2344121C2 (ru) * 2003-09-25 2009-01-20 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Способы лечения заболеваний у млекопитающих
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
DE102013011472A1 (de) * 2013-07-05 2015-01-22 Falk von Zitzewitz Vareniclin zur Behandlung nicht-stoffgebundener Abhängigkeiten
CN111686166A (zh) * 2020-08-06 2020-09-22 四川省中医药科学院 用于减轻戒烟症状的藤椒提取物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
US6235534B1 (en) * 1998-04-27 2001-05-22 Ronald Frederich Brookes Incremental absorbance scanning of liquid in dispensing tips
AU749831B2 (en) * 1998-04-29 2002-07-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP1082306A1 (en) * 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
UA73421C2 (en) * 2001-05-14 2005-07-15 Pfizer Prod Inc Cytrate salt 5,8,14-triazatetracyclo[10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaene and a pharmaceutical composition based thereon
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands

Also Published As

Publication number Publication date
CA2535811A1 (en) 2005-03-03
WO2005018621A1 (en) 2005-03-03
JP2007503425A (ja) 2007-02-22
BRPI0413607A (pt) 2006-10-17
EP1658058A1 (en) 2006-05-24
US20050043407A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
Quinn et al. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users
Mansour-Ghanaei et al. Effect of oral naltrexone on pruritus in cholestatic patients
EA200970369A1 (ru) Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
HK1064614A1 (en) Use of methylnaltrexone to treat immune suppression
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
WO2007088489A3 (en) Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
ATE414515T1 (de) Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
EP1078637A3 (en) Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
MX2007006063A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
WO2008069970A3 (en) Nicotine formulations, kits and systems and methods for their use
GB0001449D0 (en) Compositions
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2003068159A3 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
MXPA06002025A (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
MXPA05012088A (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion a nicotina en un mamifero.
MX2007012814A (es) Metodo de tratamiento utilizando un antagonista de la hormona del crecimiento y un agonista de la somatostatina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal